Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple flowchart improve Alzheimer's blood test conversations?

NCT ID NCT07812337

Diagnosis Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers at the University of Wisconsin, Madison are testing a decision-support tool that helps primary care providers talk with patients about blood biomarker testing for Alzheimer's disease. The tool is a flowchart that gives clear information about the Phospho-Tau blood test and guides discussions about memory problems. The study compares clinical encounters where providers use the tool with those where they do not, to see if the tool improves shared decision-making. About 70 people, including primary care providers and older adults with memory concerns, will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a shared decision-making support tool for discussing Alzheimer's blood biomarker testing
What this could lead to
If the tool works, it could help primary care providers and patients have clearer, more informed conversations about Alzheimer's blood tests. That may lead to better decisions about memory evaluations.
What could go wrong
This is a small pilot study with 70 participants, so results may not apply widely. The tool might not improve decision-making or could be hard for busy clinics to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Simulation 1 and Simulation 2: PCPs with experience and interest in cognitive diagnosis. * Simulation 2: community dwelling older adults age 50 or older are eligible. Exclusion Criteria (PCP): none Participant Exclusion Criteria: * Not fluent in English * age \<50 years * pre-existing diagnosis of cognitive impairment * having an activated medical decision-make r or not living independently in the community. There will be no exclusion based upon sex/gender, race, or ethnicity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive abnormality are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease cognitive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive abnormality

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • School of Medicine and Public Health, University of Wisconsin

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.